---
id: 074
title: Influenza Antivirals (Oseltamivir, Zanamivir, Baloxavir)
category: antimicrobials
subcategory: antivirals_influenza
tags: [oseltamivir, zanamivir, baloxavir, neuraminidase-inhibitors, influenza]
difficulty: medium
---

## Question

What are the mechanisms of influenza antivirals? Use the **"NAI vs CAP-DEP"** mnemonic.

## Answer

### **"NAI vs CAP-DEP" Mnemonic:**

**NAI (Neuraminidase Inhibitors):**
- **N**euraminidase enzyme target
- **A**ll influenza A & B covered
- **I**nhibits viral release (oseltamivir, zanamivir)

**CAP-DEP (Cap-Dependent Endonuclease Inhibitor):**
- **C**ap-dependent endonuclease (PA enzyme)
- **A**lternative mechanism (baloxavir)
- **P**revents viral mRNA synthesis

**DEP:**
- **D**ose: single dose (baloxavir)
- **E**arly use critical (<48hrs)
- **P**roduces rapid viral clearance

### **Comparison:**

| Drug | Mechanism | Dosing | Key Features |
|------|-----------|--------|--------------|
| **Oseltamivir** (Tamiflu) | **Neuraminidase inhibitor** | 75mg PO BID × 5d | Most common, oral |
| **Zanamivir** (Relenza) | **Neuraminidase inhibitor** | 10mg inhaled BID × 5d | Avoid in asthma |
| **Baloxavir** (Xofluza) | **Cap-dependent endonuclease** | **40-80mg PO × 1 dose** | Single dose, newest |

### **Neuraminidase Inhibitors (Oseltamivir/Zanamivir):**

**Mechanism:**
- Inhibit **neuraminidase** enzyme on viral surface
- Prevents **viral release** from infected cells
- **Reduces viral spread** to other cells

**Efficacy:**
- Reduces symptom duration by **1-1.5 days** (if started <48 hrs)
- Decreases complications (pneumonia, hospitalization)
- **Must start within 48 hours** of symptom onset

### **Baloxavir (Xofluza):**

**Mechanism:**
- Inhibits **PA endonuclease** (cap-dependent)
- Blocks viral mRNA synthesis (earlier step)
- **Single dose** treatment

**Advantages:**
- One dose (vs 5 days for NAIs)
- **Faster viral clearance**
- Alternative mechanism

**Disadvantages:**
- Resistance can emerge rapidly (I38 mutations)
- More expensive
- Less clinical data than oseltamivir

## Key Points

### **Indications:**
- **Treatment:** Suspected/confirmed influenza within **48 hours** of symptom onset
- **Prophylaxis:** Household exposure, outbreak control

### **Who to Treat:**
- **Always treat:** Hospitalized patients, severe disease (regardless of timing)
- **Consider treating:** High-risk patients (elderly, pregnancy, immunocompromised, chronic conditions)
- **Outpatients:** Benefit if <48 hours from onset

### **Resistance:**
- **Oseltamivir resistance:** H1N1 variants (H275Y mutation)
- **Baloxavir resistance:** Emerging rapidly (I38T/M/F mutations in PA)
- **Cross-resistance:** NAIs don't have cross-resistance with baloxavir

### **Clinical Pearls:**
- **Start empirically** (don't wait for testing)
- **48-hour window** critical for outpatient benefit
- **Hospitalized patients:** Treat regardless of symptom duration
- **Oseltamivir** most commonly used (oral, well-tolerated)
- **Zanamivir** avoid in asthma/COPD (bronchospasm risk)

## Sources

- [IDSA/CDC: Influenza Treatment Guidelines]
- [FDA: Baloxavir Approval 2018]

## Media

N/A
